The AML Hub was pleased to speak with Cristina Papayannidis, Universitaria di Bologna, Bologna, IT. We asked, How do you treat a patient with DNMT3A-mutated acute myeloid leukemia (AML) in remission post intensive chemotherapy?

This educational resource is independently supported by Bristol Myers Squibb. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.

Hosted on Acast. See acast.com/privacy for more information.

The AML Hub was pleased to speak with Gail Roboz, Weill Cornell Medicine, New York, US. We asked, What is the impact of the 5th World Health Organization (WHO) classification and International Consensus Classification (ICC) of AML on diagnosis and treatment of high-risk acute myeloid leukemia (HR AML)​?

In this interview, Roboz walks through the changes in the classification criteria for AML over the last 50 years, highlighting the implications of these changes and the lack of consensus on the diagnosis and management strategies for patients. Roboz goes on to discuss both classification and prognostic risk stratification tools to aid in the development of management strategies, including in HR AML, and concludes by highlighting the importance of considering patient preferences and health when making clinical decisions.

This educational resource is independently supported by Jazz Pharmaceuticals. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.

Hosted on Acast. See acast.com/privacy for more information.

Hosted on Acast. See acast.com/privacy for more information.

Hosted on Acast. See acast.com/privacy for more information.

The AML Hub was pleased to speak to Gail Roboz, Weill Cornell Medicine, New York, US, and Naval Daver, MD Anderson Cancer Center, Houston, US. We asked about risk stratification and guidelines in acute myeloid leukemia (AML) management.

Firstly, Roboz and Daver discuss the impact of blast count on the diagnosis of AML and how a patient's mutational profile can affect treatment decisions. They highlight available, effective lower-intensity and targeted therapies and a potential transition to a fully genomic- and cytogenetic-based classification of AML. Finally, they discuss current patient selection strategies for intensive induction chemotherapy and future directions in AML treatment.

Hosted on Acast. See acast.com/privacy for more information.

During the virtual 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke with Eleni Gavriilaki, George Papanikolaou General Hospital of Thessaloniki, Thessaloniki, GR. We asked, How are new fludarabine conditioning combinations impacting transplant outcomes?

Gavriilaki begins by discussing a study presented at EBMT 2022 that explored outcomes of fludarabine + treosulfan, which followed on from previous studies exploring treosulfan. Gavriilaki details the study design and patient population, explaining which comparative therapies were used and why. Finally, Gavriilaki outlines different studies presented at EBMT covering fludarabine combinations for patients with AML and MDS.

Hosted on Acast. See acast.com/privacy for more information.